UBS analyst Trung Huynh lowered the firm’s price target on Cabaletta Bio (CABA) to $7 from $10 and keeps a Buy rating on the shares. A new Gr3 ICANS case has been flagged, but appears to be related to protocol deviation, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CABA:
- Cabaletta Bio price target lowered to $22 from $30 at Morgan Stanley
- Cabaletta Bio: Strong Clinical Progress and Financial Stability Drive Buy Rating
- Cabaletta Bio price target lowered to $3 from $6 at Wells Fargo
- Cabaletta Bio price target lowered to $13 from $26 at Stifel
- Rocket acquires Mr. Cooper, Musk’s xAI acquires X: Morning Buzz